Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
November 18, 2024 07:00 ET
|
https://immatics.com/
The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics Today, Company discloses first clinical...
Quell Therapeutics Achieves Milestone for Type 1 Diabetes CAR-Treg Cell Therapy Program
November 18, 2024 04:00 ET
|
Quell TX
Achievement of first significant research milestone triggers an option exercise payment of $10 million from AstraZenecaAstraZeneca will progress preclinical and clinical development of the selected...
Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
November 12, 2024 16:05 ET
|
Turnstone Biologics Corp.
Turnstone reports third quarter 2024 financial results and provides recent business highlights
Cherry T. Thomas, M.D., Joins Wugen as Chief Medical Officer, Bringing Cell Therapy Expertise Across Clinical Development, Regulatory, and Medical Affairs as the Company Embarks on a Pivotal Trial for its Investigational, Allogeneic CD7-Targeted CAR-T Cell Therapy
November 12, 2024 07:05 ET
|
Wugen
Cherry T. Thomas, M.D., Joins Wugen as Chief Medical Officer, Bringing Cell Therapy Expertise Across Clinical Development, Regulatory, and Medical Affairs
Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CART-007, in Patients with Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia or T Cell Lymphoblastic Lymphoma
November 12, 2024 07:00 ET
|
Wugen
Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CART-007
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
November 08, 2024 17:00 ET
|
https://immatics.com/
Two oral presentations and multiple posters on clinical andpreclinical-stage candidates to be presented at SITC, demonstratingthe strength of Immatics’ TCR-T PRAME franchise to target solid cancers ...
Cell And Gene Therapy Market Size to Worth USD 190.82 Billion by 2033 | Straits Research
November 07, 2024 09:30 ET
|
Straits Research Private Limited - Garner Insights
New York, United States , Nov. 07, 2024 (GLOBE NEWSWIRE) -- “Cell therapy” refers to the process of administering live cells to patients with the purpose of treating various diseases. Both...
CARGO Therapeutics to Participate in Upcoming Investor Conferences
November 05, 2024 16:05 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics to Participate in Upcoming Investor Conferences
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 05, 2024 09:01 ET
|
Turnstone Biologics Corp.
Turnstone Biologics presents preclinical data highlighting potential for Selected TIL therapy in solid tumors at SITC 2024
Outpace Bio to present new data on programmed CAR T cell candidate OPB-101 at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 05, 2024 09:00 ET
|
Outpace Bio
Outpace Bio at SITC 2024: AI-powered OPB-101 CAR T cells show lasting functional persistence, enhanced anti-tumor activity, & stem central memory phenotype